Apitope Announces Completion of Enrolment in Phase IIA Clinical Trial Multiple Sclerosis drug

10-Aug-2015 - Apitope announced that its partner, Merck Serono, has completed patient enrolment for the Phase IIa study of ATX-MS-1467, an investigational immune-tolerising agent. It is currently being tested in an open-label, one-arm proof-of-principle trial to evaluate its safety and effect on immune ...

Apitope appoints Dr. Martin Sims as Research Director

11-Jan-2011 - Apitope International N.V. announced that Dr. Martin Sims will join the Senior Management team as Research Director with immediate effect. Martin will be responsible for Apitope’s research operations, working closely with the Chief Scientific Officer (CSO), Professor David Wraith, to guide the ...

Apitope and Merck Serono Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis

15-Jan-2009 - Apitope Technology (Bristol) Ltd., a wholly owned subsidiary of Apitope International NV, announced the signature of a research, development and commercialization agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany. Under this agreement, Apitope has granted exclusive ...

Apitope's ATX-MS-1467 shows positive immunological data in Multiple Sclerosis

Final Phase I/IIa data shows safety and tolerability, plus efficacy

05-Feb-2008 - Apitope Technology (Bristol) Ltd., developer of peptide-based therapies for autoimmune diseases and allergy, announces today final results of a Phase I/IIa clinical trial of ATX-MS-1467 to treat Multiple Sclerosis (MS). Immunological analyses showed a significant down regulation of the T-cell ...